TCGA-E2-A10C-01A-21R-A10J-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 41
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.330
- ALLOGRAFT_REJECTION+0.310
- INTERFERON_ALPHA_RESPONSE+0.310
- INTERFERON_GAMMA_RESPONSE+0.240
- FATTY_ACID_METABOLISM+0.130
- XENOBIOTIC_METABOLISM+0.090
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.070
- KRAS_SIGNALING_DN+0.060
- DNA_REPAIR+0.050
- BILE_ACID_METABOLISM+0.020
Top 10 suppressed
- TGF_BETA_SIGNALING-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- UV_RESPONSE_DN-0.410
- MITOTIC_SPINDLE-0.400
- NOTCH_SIGNALING-0.360
- TNFA_SIGNALING_VIA_NFKB-0.300
- HYPOXIA-0.290
- APICAL_JUNCTION-0.270
- PROTEIN_SECRETION-0.270
- HEDGEHOG_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-64-5778-01A-01R-1628-07 | — | cohortA1 | 0.820 |
| 2 | TCGA-73-7499-01A-11R-2187-07 | — | cohortA1 | 0.797 |
| 3 | TCGA-CV-A461-01A-41R-A266-07 | — | — | 0.788 |
| 4 | TCGA-IQ-A61I-01A-11R-A30B-07 | — | — | 0.786 |
| 5 | MDT-AP-2288 | Med | Medulloblastoma | 0.770 |
| 6 | ERR2598282 | fetal | fetal | 0.767 |
| 7 | 399e5b76-1d8d-4db9-a186-ffdc2f6e0884 | — | — | 0.766 |
| 8 | TCGA-GC-A6I3-01A-11R-A31N-07 | — | — | 0.763 |
| 9 | bd9c63e1-a1cb-4b2f-a909-839ce2fd8618 | — | — | 0.763 |
| 10 | TCGA-P3-A5Q5-01A-11R-A28V-07 | — | — | 0.761 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.020 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |